United Therapeutics Corp
Company Profile
Business description
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Contact
1000 Spring Street
Silver SpringMD20910
USAT: +1 301 608-9292
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,305
Stocks News & Analysis
stocks
16 ASX stocks to buy and hold forever, revisited
stocks
This ASX200 reject could be a contrarian buying opportunity
stocks
A 15 step checklist from Buffett's forgotten inspiration
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,002.60 | 100.80 | -1.24% |
| CAC 40 | 7,988.96 | 47.05 | 0.59% |
| DAX 40 | 22,676.41 | 347.64 | 1.56% |
| Dow JONES (US) | 41,449.01 | 15.53 | 0.04% |
| FTSE 100 | 8,540.97 | 44.98 | 0.53% |
| HKSE | 23,600.31 | 181.83 | -0.76% |
| NASDAQ | 17,657.20 | 221.11 | 1.27% |
| Nikkei 225 | 36,819.09 | 25.98 | 0.07% |
| NZX 50 Index | 12,249.55 | 161.42 | -1.30% |
| S&P 500 | 5,609.61 | 37.54 | 0.67% |
| S&P/ASX 200 | 7,786.20 | 103.90 | -1.32% |
| SSE Composite Index | 3,371.92 | 7.90 | -0.23% |